APOB
EmergingApoB directly counts atherogenic lipoprotein particles, now considered a superior cardiovascular risk marker to LDL-C in many patients.
ApoB counts the actual number of "bad" cholesterol particles in the blood, which turns out to be a more reliable heart-disease risk marker than the standard LDL-cholesterol number, especially in people with diabetes or obesity where the two tests can disagree.
Apolipoprotein B (APOB) is the main structural protein of LDL and other atherogenic lipoproteins; each particle carries exactly one ApoB molecule, making it a direct measure of the number of potentially harmful lipoprotein particles in blood.
Elevated ApoB indicates a higher number of atherogenic (LDL-type) particles, which current cardiology guidance considers a better cardiovascular risk marker than LDL-cholesterol concentration alone, especially in patients with diabetes, high triglycerides, obesity, or very low LDL-C, where LDL-C can be misleadingly reassuring.
The 2025 ESC/EAS focused lipid guideline update reinforces ApoB's role as a preferred cardiovascular risk marker; the National Lipid Association's proposed ApoB target is <90 mg/dL (<80 mg/dL in very-high-risk patients). Multiple 2025 studies, including a 20-year cohort study, confirm ApoB predicts cardiovascular risk independent of and beyond LDL-C.
In patients with discordant LDL-C and ApoB results (common in diabetes, obesity, or metabolic syndrome), current guidance increasingly favors using ApoB to guide statin/lipid-lowering therapy intensity decisions rather than LDL-C alone.
A major, very current (2025) cardiology guideline shift toward ApoB as a primary or co-primary lipid target.
- PMC. (2025). ESC/EAS Focused Update of the 2019 Guidelines for the Management of Dyslipidaemias.
- National Lipid Association. (2025). Apolipoprotein B Target Recommendations.